Articles related to Endocrinology, Diabetes, Metabolism

The SGLT2 inhibitor bexagliflozin is now available under the brand name Brenzavvy. Approval was based on monotherapy trials versus glimepiride, where the new drug was non-inferior, and in combination with metformin.

This summary of a January 2023 JACC article highlights the study finding that rosuvastatin was “vastly superior to… any of the six supplements studied in the trial.” The study compared rosuvastatin to cinnamon, garlic, turmeric, red yeast rice, fish oil, and plant sterols. Rosuvastatin yielded a reduction in cholesterol of nearly 38 percent in just 28 days. The supplements had little to no effect but were significantly more costly than the statin.

The authors speculate that pharmacogenomic testing can identify patients at higher risk for adverse events related to drug-drug and drug-gene interactions based on the 29-year-old man’s prescription list and gene testing results. Potential drug-drug interactions should also be investigated, and patients should be appropriately monitored for adverse reactions. Before performing pharmacogenomic testing, consider the severity of potential reactions, cost, and the possibility of using an alternative regimen that avoids the interaction of concern entirely. As more is learned about pharmacogenomics and the potential personalization of therapeutic regimens, clinical considerations that warrant testing should be evaluated on a regular basis to facilitate both resource stewardship and optimal patient care.

Guideline Central offers a complete summary of the ADA’s latest guideline — Standards of Care for 2023. The update and summary cover topics from delaying the onset of T2DM to supporting positive behaviors, glycemic targets, weigh management, technology, pharmacology, and preventing and managing complications and concomitant diseases.

Participants should be better able to discuss anti-VEGF therapy outcomes in patients with moderate-severe and severe nonproliferative diabetic retinopathy after taking part in this educational activity with Drs. Susan Bressler, Mark Dunbar, and Ruth Weinstock, and understand the importance of prompt referral and early diagnosis to reduce or even prevent the vision-threatening complications of diabetes.

A layered approach to care is described with lifestyle interventions being a key feature of the updated recommendations. The recommendations now include therapies proven to improve cardiovascular and kidney outcomes in patients with diabetes and CKD.